Highest-materiality recent filing
Merit Medical shareholders approve 2.7M-share 2026 Equity Plan and re-elect all directors
Shareholders approved 2.7M share 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at May 13 annual meeting.
Merit Medical Q1 beat: rev $381.9M, EPS $0.94 non-GAAP; acquires View Point Medical for $140M
Revenue $381.9M (+7%); GAAP EPS $0.68 (+39%); non-GAAP EPS $0.94 (+9%).
Merit Medical Systems provides historical revenue by new product categories for 2022-2025
Total revenue grew from $1.151B in 2022 to $1.516B in 2025, with foundational revenue at $1.029B and therapeutic at $487M in 2025.
Merit Medical acquires View Point Medical for ~$140M; 2027 non-GAAP EPS accretive
Total consideration ~$140M; $90M cash at closing, $25M deferred at each of first and second anniversaries.
Merit Medical Q4 revenue $393.9M (+11% YoY); guides FY2026 EPS $4.01-$4.15
Q4 revenue $393.9M (+11% YoY); GAAP EPS $0.63 (+37%); Non-GAAP EPS $1.04 (+12%).
Merit Medical founder Lampropoulos resigns as Chair; preliminary Q4 revenue up ~10-11% YoY
Fred P. Lampropoulos resigned as director and Chair on Jan 4, after earlier stepping down as CEO and Executive Chair; three-month consulting agreement at $250K/month.
Merit Medical withdraws WRAPSODY TPT application; CMS deferral delays payment to Jan 2027
CMS deferred Merit's Transitional Pass-Through incremental payment application for WRAPSODY CIE to CY2027 rule; Jan 1, 2027 earliest effective date.
Merit Medical closes C2 CryoBalloon acquisition from PENTAX Medical
Acquired C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical.
Merit Medical Q3 revenue $384.2M (+13%), non-GAAP EPS $0.92 (+6.7%), updates FY guidance
Q3 revenue $384.2M (+13.0% YoY); constant currency organic revenue +7.8%.
Merit Medical signs $22M asset deal to acquire C2 CryoBalloon from PENTAX Medical
Total consideration $22M: $19M cash at closing plus up to $3M in milestone payments.
Martha Aronson named CEO of Merit Medical as Fred Lampropoulos resigns; remains Chairman
Aronson appointed President and CEO effective Oct 3, 2025; Lampropoulos resigns as CEO but stays as director and Chairman.
Merit Medical Q2 revenue up 13.2% to $382.5M; non-GAAP EPS $1.01, up 9.8%; appoints new CEO
Revenue $382.5M, +13.2% YoY; constant-currency revenue +12.5%, organic constant-currency +6.7%.
Merit Medical names Martha Aronson as CEO effective Oct 3; preliminary Q2 revenue up ~12-14% YoY
Martha Aronson appointed President and CEO effective Oct 3, 2025; founder Fred Lampropoulos remains Chairman.
Merit Medical acquires Biolife for $120M in cash; adds StatSeal/WoundSeal hemostasis products
Purchase price $120M cash; Biolife becomes wholly-owned subsidiary of Merit.
Merit Medical shareholders elect 4 directors, approve say-on-pay, ratify Deloitte
Directors Gunderson, Kaiser, McDonnell, Millner each elected with >48M votes for.
Merit Medical Q1 2025 revenue $355.4M up 9.8% YoY; non-GAAP EPS $0.86 up 14.8%
GAAP EPS $0.49 up 2.0%; non-GAAP EPS $0.86 up 14.8% vs Q1 2024.
Merit Medical Q4 revenue $355M (+9.4%); Non-GAAP EPS $0.93 (+25.8%); FY 2025 guidance issued
Q4 2024 revenue $355.2M, up 9.4% YoY; constant currency revenue up 10.1%; organic constant currency up 6.1%.
Merit Medical hosts investor call on WRAPSODY CIE; prepared remarks truncated in filing
Conference call held January 28, 2025, to discuss commercial and marketing updates for the WRAPSODY CIE stent-graft.
Merit Medical prelim FY2024 rev ~$1.356B, up 7.7-7.9% YoY; full results Feb 25
Preliminary unaudited revenue $1.355B-$1.357B for FY2024, up ~7.7%-7.9% YoY.
President Joseph C. Wright resigns effective Jan 3, 2025, following allegations investigated by independent directors.
Merit Medical completes $210M cash acquisition of Cook Medical's lead management portfolio
Closed on November 1, 2024; consideration ~$210M cash plus assumption of certain liabilities.
Merit Medical Q3 revenue up 7.8% to $339.8M, non-GAAP EPS $0.86, raises guidance
Revenue $339.8M (+7.8% YoY); GAAP EPS $0.48 (+8.0%); non-GAAP EPS $0.86 (+21.1%).
Acquires Cook Medical's lead management portfolio for ~$210M cash; closing expected in Q4 2024.
Merit Medical Q2 revenue $338M (+5.6%), GAAP EPS $0.61 (+75.7%), raises FY guidance
Revenue $338.0M, up 5.6% YoY; constant currency revenue up 6.6%.
Merit Medical acquires EndoGastric Solutions' EsophyX Z+ device for $105M; updates 2024 guidance
Asset purchase of EsophyX Z+ device for $105M cash, financed via credit facility draws.
Merit shareholders elect Silvia M. Perez as director; bylaws updated for new President role
Silvia M. Perez, President of 3M's Commercial Branding & Transportation Division, elected to Board for three-year term.
Merit Medical appoints Joe Wright President; Lampropoulos remains CEO
Joseph C. Wright appointed President effective May 15, 2024, succeeding Fred Lampropoulos, who remains CEO.
Merit Medical Q1 2024 revenue $323.5M (+8.7% YoY); GAAP EPS $0.48 (+35.5%)
Revenue $323.5M, up 8.7% YoY; constant currency revenue up 9.3%; organic constant currency up 7.0%.
In connection with Mr. Wright’s appointment, Fred P. Lampropoulos resigned as President of Merit. Mr. Lampropoulos will continue to serve as Merit’s Chief Executive Officer.
The Board of Directors of Merit Medical Systems, Inc. (“Merit”) appointed Joseph C. Wright as President of Merit, effective as of May 15, 2024.
Max materiality 0.85 · Median 0.70 · Most common event earnings